Posted 06 November, 2023

Lexeo Therapeutics, Inc. IPO completed

IPO completed detected for ticker Nasdaq:LXEO in a 424B4 filed on 06 November, 2023.

  This is an initial public offering of shares of common stock of Lexeo Therapeutics, Inc.  

Don't know how to trade IPO completion? Read Initial Public Offerings.
Overview of Lexeo Therapeutics, Inc.
Health Care/Life Sciences • Biotechnology
Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The firm focuses on the medication of genetically defined cardiovascular diseases and sub-group of Alzheimer’s disease. It offers LX2006 for the treatment of patients with Friedreich's ataxia, cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer's disease. The company was founded by Ronald G. Crystal in February 2017 and is headquartered in New York, NY.
Market Cap
View Company Details